0001209191-19-019509.txt : 20190314
0001209191-19-019509.hdr.sgml : 20190314
20190314171348
ACCESSION NUMBER: 0001209191-19-019509
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190312
FILED AS OF DATE: 20190314
DATE AS OF CHANGE: 20190314
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Menzaghi Frederique Ph.D.
CENTRAL INDEX KEY: 0001597152
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36279
FILM NUMBER: 19681896
MAIL ADDRESS:
STREET 1: C/O CARA THERAPEUTICS, INC.
STREET 2: 1 PARROTT DRIVE
CITY: SHELTON
STATE: CT
ZIP: 06484
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001346830
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4 STAMFORD PLAZA
STREET 2: 107 ELM STREET 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06902
BUSINESS PHONE: 203-406-3700
MAIL ADDRESS:
STREET 1: 4 STAMFORD PLAZA
STREET 2: 107 ELM STREET 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06902
FORMER COMPANY:
FORMER CONFORMED NAME: Cara Therapeutics Inc
DATE OF NAME CHANGE: 20051213
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-03-12
0
0001346830
Cara Therapeutics, Inc.
CARA
0001597152
Menzaghi Frederique Ph.D.
C/O CARA THERAPEUTICS, INC.
4 STAMFORD PLAZA, 107 ELM ST, 9TH FLOOR
STAMFORD
CT
06902
0
1
0
0
Chief Scientific Off,SVP-R&D
Common Stock
2019-03-12
4
S
0
3197
17.50
D
139582
D
Common Stock
2019-03-13
4
S
0
16803
18.87
D
122779
D
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $17.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.21 to $19.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
/s/Darren DeStefano, Attorney-in-Fact
2019-03-14